SWSeamus P. Whelton

Seamus P. Whelton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seamus P. Whelton has a total of 387 co-authors. Here are the top co-authors by number of shared publications:

  • Michael J. Blaha

    Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States

    20 shared publications
  • Roger S. Blumenthal

    Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    17 shared publications
  • Khurram Nasir

    Division of Cardiovascular Prevention and Wellness, DeBakey Heart and Vascular Institute, Houston Methodist , Houston, TX

    14 shared publications
  • Matthew J. Budoff

    Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, United States

    13 shared publications
  • Alexander C. Razavi

    Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA (A.C.R.).

    12 shared publications
  • Alexander C. Razavi

    Center for Heart Disease Prevention, Emory University School of Medicine, Atlanta, GA, United States

    11 shared publications

Latest Publications

  • Impact of computed tomography-derived fractional flow reserve on long-term outcomes in patients with stable coronary artery disease: A systematic review and meta-analysis

    by Claudio Laudani, Jorge Sanz-Sanchez, Pablo M. Rubio, Agostina A. Sanchez, Prashant Nagpal, Abdulhamied Alfaddagh, Daniele Andreini, Andrea Baggiano, Arzu Canan, Anjali Chelliah, et al.

  • Open Access

    Association of Polygenic Risk Scores With Aortic Valve Calcium: The Multi‐Ethnic Study of Atherosclerosis

    by Seamus P. Whelton, Jie Yao, Clary Clish, Alexis C. Wood, Kent D. Taylor, Michael J. Blaha, Matthew Budoff, Natalie Marrero, George Thanassoulis, Wendy S. Post, et al.

    Background: Aortic valve calcification (AVC) is the primary process leading to aortic stenosis. We examined whether polygenic risk scores (PRS) are associated with AVC beyond traditional atherosclerotic cardiovascular disease risk factors. Methods: We included 6812 participants in MESA (Multi‐Ethnic Study of Atherosclerosis) with computed tomography‐measured AVC at Visit 1. Using previously published PRS we calculated weighted PRS, standardized within each ancestry group. The cross‐sectional association per 1 SD higher PRS with AVC >0 was examined using multivariable logistic regression modeling with Bonferroni correction. The mean age was 62 years old, 53% were female, and 913 (13.4%) had AVC >0 at baseline. Results: The PRS for coronary artery disease (hazard ratio [HR], 1.16 [95% CI, 1.07–1.26]), systolic blood pressure (HR, 1.1 [95% CI, 1.020–1.2]), low‐density lipoprotein cholesterol (HR, 1.16 [95% CI, 1.06–1.25]), and lipoprotein(a) (HR, 1.11 [95% CI, 1.02–1.20]) were significantly associated with AVC, whereas the other PRS including coronary artery calcium (HR, 1.02 [95% CI, 0.94–1.10]) and C‐reactive protein (HR, 0.97 [95% CI, 0.89–1.05]) were not. In sex‐stratified analyses, the PRS for coronary artery disease, low‐density lipoprotein cholesterol, and lipoprotein(a) were significantly associated with AVC >0 for both sexes ( P 0 strongly suggests significant differences exist in the calcification pathways for AVC and coronary artery calcium.


  • Sex-Specific Prognostic Value of Aortic Valve Calcium and the Risk for Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis (MESA)

    by Natalie Marrero, Kunal Jha, Jelani K. Grant, Alexander C. Razavi, Matthew J. Budoff, Sanjiv J. Shah, Jerome I. Rotter, Roger S. Blumenthal, Wendy S. Post, Martha Gulati, et al.

    BACKGROUND: In general, women have lower aortic valve calcium (AVC) scores compared with men of similar age, and the AVC score threshold for diagnosing severe aortic stenosis (AS) is lower for women. We examined whether the association of AVC with the long-term risk of clinically significant AS differed for women compared with men. METHODS: AVC was measured using cardiac computed tomography among 6810 MESA (Multi-Ethnic Study of Atherosclerosis) participants. We examined AVC as a continuous (ln [AVC+1]) and categorical variable (0, 1–99, 100–299, ≥300 AU). Incident moderate or severe AS was adjudicated using standard clinical criteria with a median follow-up of 16 years. The association between AVC and AS was examined using multivariable-adjusted Cox proportional hazards regression. RESULTS: Women comprised 52.9% of participants, with AVC >0 present among 10.1% of women and 17.0% of men. There were 65 cases of incident AS in women and 75 in men. AVC as a continuous variable was associated with a higher risk of incident AS for women (hazard ratio, 1.91 [95% CI, 1.68–2.16]) and men (hazard ratio, 2.13 [95% CI, 1.88–2.41]). There was no interaction between AVC and sex ( P =0.31) for their association with AS. Women and men had similar adjusted hazards for incident AS across AVC categories, and for those with AVC ≥300, the hazard ratio was 134.9 (95% CI, 45.1–403.9) for women and 132.8 (95% CI, 6.2–274.9) for men. CONCLUSIONS: The association of AVC with the long-term risk of incident AS was similar for women and men, further supporting the utility of AVC as a prognostic marker for incident AS.


  • Open Access

    Association Between Lipoprotein(a) and Cardiac Remodeling Across Race and Ethnicity in the Multi-Ethnic Study of Atherosclerosis

    by Ashkan Abdollahi, Aysa Ostovaneh, Omar Chehab, Malak Hoballah, Bruna R.S. Matuck, Colin O. Wu, Seamus P. Whelton, Bharath Ambale-Venkatesh, Wendy S. Post, David A. Bluemke, et al.

    BACKGROUND: Lp(a) (lipoprotein[a]) is a known cardiovascular risk factor; however, its role in cardiac remodeling and functional changes over time across diverse racial and ethnic groups remains underexplored. METHODS: MESA is a prospective multi-ethnic cohort study of individuals without a history of cardiovascular disease on enrollment (2000–2002), conducted across 6 sites in the United States. Participants with baseline Lp(a) measurements and cardiac magnetic resonance imaging at both baseline and 10-year follow-up exam were included. Lp(a) was treated as both a log-transformed continuous variable (per SD log) and a categorical variable based on data-driven Lp(a) terciles. Multivariable regression models adjusted for sociodemographic, and cardiovascular risk factors, including coronary artery calcium and interim myocardial infarction, were used to assess associations between Lp(a) and longitudinal changes in left ventricular and atrial structure and function over a decade across different racial/ethnic groups. RESULTS: A total of 2366 participants were included. The average age at baseline was 60±9 with 53% women, 43% White, 24% Black, 21% Hispanic, and 12% Chinese. Each 1-SD increase in log-transformed Lp(a) was associated with an increase in left ventricular end-systolic volume index (β, 0.60 [95% CI, 0.02–1.18]), and left atrial minimum volume index (β, 0.81 [95% CI, 0.09–1.52]), and a decline in left ventricular ejection fraction (β, −0.75 [95% CI, −1.34 to −0.17]), and total left atrial emptying fraction (β, −1.17 [95% CI, −2.09 to −0.24]) in Hispanic subjects over a decade. No significant associations were seen in White, Black, or Chinese participants. The observed findings persisted after adjusting for coronary artery calcium, interim myocardial infarction, and atrioventricular decoupling, and when Lp(a) was treated as a categorical variable with race-specific terciles. CONCLUSIONS: Elevated Lp(a) levels were independently associated with maladaptive left ventricular and left atrial remodeling in Hispanic adults over a decade, while no statistically significant relationships were observed in White, Black, and Chinese participants. This suggests a unique susceptibility of Hispanic individuals to Lp(a)-mediated cardiovascular remodeling, independent of ischemic pathways.


  • Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis

    by Alexander C Razavi, Harpreet S Bhatia, Natalie Marrero, Omar Dzaye, Wendy S Post, Khurram Nasir, Michael Tsai, Viola Vaccarino, Ramachandran S Vasan, George Thanassoulis, et al.

    Background and Aims: Lipoprotein(a) [Lp(a)] and LDL cholesterol (LDL-C) are causally linked to aortic valve calcium (AVC) and aortic stenosis (AS). Lipoprotein(a) has anti-fibrinolytic properties; therefore, aspirin may reduce cardiovascular disease risk among individuals with high Lp(a). This analysis sought to determine the association of aspirin with incident AVC and AS across Lp(a) and LDL-C levels. Methods: This observational study included up to 6598 participants in the Multi-Ethnic Study of Atherosclerosis. Aortic valve calcium was measured on non-contrast cardiac computed tomography. Multivariable Cox hazards regression assessed the association of self-reported regular aspirin use (≥3 days/week) with incident AVC and severe AS, stratified by Lp(a) and LDL-C. Aortic valve calcium and Lp(a) values were not reported to participants. Results: Mean age was 62 years, 53% were women, 23% reported regular aspirin use, 8% developed AVC (median 8.9 years), and 1% developed severe AS (median 16.7 years). Among individuals with elevated Lp(a), regular aspirin use was associated with a lower risk of incident AVC (Lp(a) ≥75 mg/dL: hazard ratio (HR) .42, 95% confidence interval (CI) .19–.93; Lp(a) ≥100 mg/dL: HR .17, 95% CI .04–.67) and severe AS (Lp(a) ≥50 mg/dL: HR .13, 95% CI: .04–.47; Lp(a) ≥75 mg/dL: HR .02, 95% CI .001–.29). For participants with elevated LDL-C, there was no association of regular aspirin use with incident AVC (LDL-C ≥130 mg/dL: HR 1.02, 95% CI .66–1.58; LDL-C ≥160 mg/dL: HR 1.51, 95% CI .53–4.28) or severe AS (LDL-C ≥100 mg/dL: HR .70, 95% CI .39–1.26; LDL-C ≥130 mg/dL: HR .46, 95% CI .14–1.47). Conclusions: In this exploratory analysis of prospective observational cohort data, regular aspirin use was associated with a lower risk of AVC and severe AS in persons with high Lp(a), but not high LDL-C. Confirmatory studies are required to determine the role of aspirin in the prevention of AVC and AS for persons with high Lp(a).


  • Race and Ethnic-Specific Burden of Aortic Valve Calcium and Its Association With Long-Term Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis

    by Jelani K. Grant, Kunal Jha, Natalie Marrero, Alexander C. Razavi, Ellen Boakye, Khalil Anchouche, Omar Dzaye, Matthew J. Budoff, Sanjiv J. Shah, Matthew J. Czarny, et al.

    BACKGROUND: Racial and ethnic differences have been reported for aortic valve calcium (AVC) and long-term aortic stenosis (AS). Whether these differences are due to differing risk factor profiles or the burden of AVC is unknown. METHODS: Baseline AVC was quantified using the Agatston method among 6812 MESA (Multi-Ethnic Study of Atherosclerosis) participants. AVC scores were not reported to participants. The primary outcome of long-term moderate or severe AS was adjudicated using standard clinical criteria. We calculated multivariable Cox proportional hazards with log-transformed AVC as a continuous variable for each race and ethnicity. RESULTS: The mean age was 62 years, and 47% of participants were women. Over a median follow-up of 16.7 years, 140 participants were diagnosed with moderate (n=56) and severe AS (n=84). The prevalence of baseline AVC >0 by self-reported race and ethnicity was White (15.8%), Hispanic (13.3%), Black (12.3%), and Chinese (8.3%). The rate of long-term incident moderate-severe AS was highest for White participants (2.1/1000 person-years) and lowest for Chinese participants (0.5/1000 person-years). The association of AVC with moderate-severe AS was significant for all race and ethnicity groups: White hazard ratio, 1.82 (95% CI, 1.62–2.03); Hispanic hazard ratio, 2.18 (95% CI, 1.82–2.62); Black hazard ratio, 2.28 (95% CI, 1.78–2.93); and Chinese hazard ratio, 3.65 (95% CI, 1.05–12.71) per 1 unit higher log transformed AVC. There was no interaction by race and ethnicity ( P =0.26) when modeling Black versus non-Black participants. CONCLUSIONS: The racial and ethnic groups with a higher baseline prevalence of AVC had a higher long-term incidence of moderate-severe AS, but a similar relative association between AVC and moderate-severe AS regardless of baseline atherosclerotic cardiovascular disease risk. Our findings suggest that differences in AS by race and ethnicity may likely be explained by the burden of AVC.


  • Open Access

    Progress in risk assessment and management: Forecasting updates across international cholesterol guidelines

    by Alexander C. Razavi, Mark Sokolsky, Matthew Belanger, Cameron Blazoski, Jared A. Spitz, Laurence S. Sperling, Roger S. Blumenthal, Seamus P. Whelton


  • Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension

    by Konstantin A. Krychtiuk, Renato D. Lopes, Victoria A Cargill, Roland Chen, Martin R. Cowie, William C. Cushman, Mitchell S.V. Elkind, Shilpi Epstein, Pushkal P. Garg, Bernard J. Gersh, et al.

    Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox—blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.


  • Impact of age on aortic valve calcium progression and risk for aortic stenosis: multi-ethnic study of atherosclerosis

    by Natalie Marrero, Kunal Jha, Jelani Grant, Alexander C Razavi, Matthew J Budoff, Sanjiv J Shah, Jerome I Rotter, Roger S Blumenthal, Wendy S Post, Leslee J Shaw, et al.

    Aims: Aortic valve calcium (AVC) is strongly associated with the risk for severe aortic stenosis (AS). The prevalence of AVC increases with age, but the impact of age on the progression of AVC and its association with moderate-severe AS is unknown. Methods and results: Our study included 6810 participants (52.9% women) without overt cardiovascular disease between ages 45 and 84 from the Multi-Ethnic Study of Atherosclerosis. AVC was measured using non-contrast cardiac CT at Visit 1. Progression was calculated as the change in AVC divided by years between CT scans (2–10 years). Incident moderate-severe AS was adjudicated using medical chart review and echocardiogram data from Visit 6 (median follow-up of 16 years). The association between AVC and moderate-severe AS was assessed using multivariable adjusted Cox proportional hazards ratios. There were 5899 participants with AVC = 0 and 911 with AVC >0. There were 3834 participants age <65 years and 2979 age ≥65 years. The median AVC was 34.1 AU (IQR 13–1113) for participants <65 vs. 69.0 AU (IQR 23–2453) for participants ≥65. Participants 0 was associated with a similar significantly higher risk of incident moderate-severe AS for both younger (HR 13.37; 95% CI 5.67–31.52) and older participants (HR 10.59, 95% CI 6.77–16.56). Conclusion: AVC progression was significantly associated with baseline AVC burden and was similar for younger vs. older persons after accounting for baseline AVC. The presence of AVC was significantly associated with a higher long-term risk for moderate-severe AS among both younger and older participants.


  • Colchicine: Evidence to Treat or Equipoise?

    by Seamus P. Whelton, Roger S. Blumenthal, Wendy S. Post